Trial Profile
Short term tapering of Ruxolitinib prior conditioning therapy with allogeneic stem cell transplantation for primary myelofibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2017
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Pharmacodynamics; Therapeutic Use
- 21 Oct 2017 Status changed from recruiting to completed.
- 27 Oct 2015 New trial record